GlassScriptPhysician profile
Sean R Chappin
NPI 1679740427
$20,323.54
in general payments reported to CMS, 2019-2025
30 companies · $4,937 in 2025
The $4,937 reported for 2025 was more than what 91% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,909 · 2020: $1,329 · 2021: $2,577 · 2022: $2,463 · 2023: $3,061 · 2024: $4,047 · 2025: $4,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,045.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,515.77 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,359.89 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,973.43 | 2019-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $1,892.62 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $1,369.00 | 2019-2025 | Rexulti, Nuedexta |
| Alkermes, INC. | $1,252.56 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,202.36 | 2019-2025 | Trintellix |
| Lundbeck LLC | $1,063.31 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $840.34 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $834.91 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $784.96 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Corium, LLC | $745.52 | 2022-2024 | Azstarys |
| Allergan, INC. | $696.41 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $605.87 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $236.54 | 2025 | Cobenfy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $218.72 | 2022-2025 | Qelbree, Qelbree |
| Orexo US, INC. | $116.05 | 2022-2025 | Zubsolv |
| Avanir Pharmaceuticals, INC. | $99.03 | 2019-2022 | |
| Shire North American Group INC | $74.02 | 2019 | |
| Eisai INC. | $68.56 | 2021 | |
| Collegium Pharmaceutical, INC. | $67.58 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $57.84 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $45.25 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $44.50 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $44.49 | 2021-2022 | |
| Janssen Biotech, INC. | $28.44 | 2024 | Spravato |
| Biogen, INC. | $27.12 | 2024 | |
| Indivior INC. | $21.94 | 2024 | Sublocade |
| Bausch Health US, LLC | $19.04 | 2019 | |
| Alfasigma USA, INC. | $17.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Chappin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.